S&P 500   3,943.04 (+0.05%)
DOW   33,651.88 (+0.17%)
QQQ   281.96 (+0.10%)
AAPL   141.98 (-0.65%)
MSFT   245.98 (+0.35%)
META   114.91 (+0.69%)
GOOGL   96.12 (-0.89%)
AMZN   88.87 (+0.70%)
TSLA   174.60 (-2.90%)
NVDA   161.34 (+0.92%)
NIO   12.45 (-5.97%)
BABA   88.39 (-3.35%)
AMD   70.92 (+0.93%)
T   19.40 (+1.20%)
MU   54.08 (+0.75%)
CGC   3.43 (-4.99%)
F   13.36 (+0.60%)
GE   86.03 (+0.88%)
DIS   92.58 (+0.31%)
AMC   6.71 (-0.59%)
PYPL   72.53 (+0.42%)
PFE   50.56 (+1.71%)
NFLX   307.00 (+0.47%)
S&P 500   3,943.04 (+0.05%)
DOW   33,651.88 (+0.17%)
QQQ   281.96 (+0.10%)
AAPL   141.98 (-0.65%)
MSFT   245.98 (+0.35%)
META   114.91 (+0.69%)
GOOGL   96.12 (-0.89%)
AMZN   88.87 (+0.70%)
TSLA   174.60 (-2.90%)
NVDA   161.34 (+0.92%)
NIO   12.45 (-5.97%)
BABA   88.39 (-3.35%)
AMD   70.92 (+0.93%)
T   19.40 (+1.20%)
MU   54.08 (+0.75%)
CGC   3.43 (-4.99%)
F   13.36 (+0.60%)
GE   86.03 (+0.88%)
DIS   92.58 (+0.31%)
AMC   6.71 (-0.59%)
PYPL   72.53 (+0.42%)
PFE   50.56 (+1.71%)
NFLX   307.00 (+0.47%)
S&P 500   3,943.04 (+0.05%)
DOW   33,651.88 (+0.17%)
QQQ   281.96 (+0.10%)
AAPL   141.98 (-0.65%)
MSFT   245.98 (+0.35%)
META   114.91 (+0.69%)
GOOGL   96.12 (-0.89%)
AMZN   88.87 (+0.70%)
TSLA   174.60 (-2.90%)
NVDA   161.34 (+0.92%)
NIO   12.45 (-5.97%)
BABA   88.39 (-3.35%)
AMD   70.92 (+0.93%)
T   19.40 (+1.20%)
MU   54.08 (+0.75%)
CGC   3.43 (-4.99%)
F   13.36 (+0.60%)
GE   86.03 (+0.88%)
DIS   92.58 (+0.31%)
AMC   6.71 (-0.59%)
PYPL   72.53 (+0.42%)
PFE   50.56 (+1.71%)
NFLX   307.00 (+0.47%)
S&P 500   3,943.04 (+0.05%)
DOW   33,651.88 (+0.17%)
QQQ   281.96 (+0.10%)
AAPL   141.98 (-0.65%)
MSFT   245.98 (+0.35%)
META   114.91 (+0.69%)
GOOGL   96.12 (-0.89%)
AMZN   88.87 (+0.70%)
TSLA   174.60 (-2.90%)
NVDA   161.34 (+0.92%)
NIO   12.45 (-5.97%)
BABA   88.39 (-3.35%)
AMD   70.92 (+0.93%)
T   19.40 (+1.20%)
MU   54.08 (+0.75%)
CGC   3.43 (-4.99%)
F   13.36 (+0.60%)
GE   86.03 (+0.88%)
DIS   92.58 (+0.31%)
AMC   6.71 (-0.59%)
PYPL   72.53 (+0.42%)
PFE   50.56 (+1.71%)
NFLX   307.00 (+0.47%)
NASDAQ:EIGR

Eiger BioPharmaceuticals - EIGR Stock Forecast, Price & News

$3.83
-0.08 (-2.05%)
(As of 12/7/2022 10:54 AM ET)
Add
Compare
Today's Range
$3.71
$3.91
50-Day Range
$3.91
$8.01
52-Week Range
$3.53
$10.02
Volume
3,544 shs
Average Volume
272,087 shs
Market Capitalization
$168.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.00

Eiger BioPharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,153.3% Upside
$48.00 Price Target
Short Interest
Healthy
3.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.67
Upright™ Environmental Score
News Sentiment
0.66mentions of Eiger BioPharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.26) to ($1.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

175th out of 1,023 stocks

Biological Products, Except Diagnostic Industry

26th out of 170 stocks

EIGR stock logo

About Eiger BioPharmaceuticals (NASDAQ:EIGR) Stock

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EIGR Stock News Headlines

Scale The Eiger With This 'Sum of the Parts Trade
See More Headlines
Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EIGR Company Calendar

Last Earnings
11/04/2021
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EIGR
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.00
High Stock Price Forecast
$48.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+1,153.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-33,920,000.00
Net Margins
-660.21%
Pretax Margin
-659.90%

Debt

Sales & Book Value

Annual Sales
$12.14 million
Book Value
$2.13 per share

Miscellaneous

Free Float
40,813,000
Market Cap
$168.79 million
Optionable
Not Optionable
Beta
1.39

Key Executives

  • Mr. David A. Cory M.B.A. (Age 58)
    MBA, R.Ph, R.Ph., Bus. Founder, Pres, CEO & Director
    Comp: $1.02M
  • Dr. Jeffrey S. Glenn M.D. (Age 59)
    Ph.D., Scientific Founder & Independent Director
    Comp: $57.5k
  • Mr. Sriram Ryali M.B.A. (Age 41)
    Chief Financial Officer
    Comp: $662.94k
  • Mr. Eldon C. Mayer IIIMr. Eldon C. Mayer III (Age 61)
    M.B.A., Exec. VP & Chief Commercial Officer
    Comp: $576.18k
  • Mr. Christopher A. Kurtz (Age 55)
    Chief Technical Officer
  • Mr. Erik Atkisson (Age 50)
    Gen. Counsel, Corp. Sec. & Chief Compliance Officer
  • Dr. Ingrid C. Choong
    Sr. VP of Clinical Devel.
  • Dr. Stephana E. Patton J.D. (Age 51)
    Ph.D., Consultant
  • Mr. Rich Franco M.B.A.
    Sr. VP of Regulatory Affairs
  • Dr. Colin Hislop M.D. (Age 64)
    Sr. VP of Clinical & Devel. Operations













EIGR Stock - Frequently Asked Questions

Should I buy or sell Eiger BioPharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EIGR shares.
View EIGR analyst ratings
or view top-rated stocks.

What is Eiger BioPharmaceuticals' stock price forecast for 2023?

1 brokers have issued 1-year target prices for Eiger BioPharmaceuticals' shares. Their EIGR share price forecasts range from $48.00 to $48.00. On average, they anticipate the company's stock price to reach $48.00 in the next year. This suggests a possible upside of 1,127.6% from the stock's current price.
View analysts price targets for EIGR
or view top-rated stocks among Wall Street analysts.

How have EIGR shares performed in 2022?

Eiger BioPharmaceuticals' stock was trading at $5.19 on January 1st, 2022. Since then, EIGR stock has decreased by 24.7% and is now trading at $3.91.
View the best growth stocks for 2022 here
.

Are investors shorting Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totaling 1,670,000 shares, a decrease of 8.2% from the October 31st total of 1,820,000 shares. Based on an average trading volume of 344,200 shares, the days-to-cover ratio is currently 4.9 days.
View Eiger BioPharmaceuticals' Short Interest
.

When is Eiger BioPharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our EIGR earnings forecast
.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) issued its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.07. The biotechnology company earned $3.04 million during the quarter, compared to the consensus estimate of $2.54 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 106.48% and a negative net margin of 660.21%. During the same quarter in the previous year, the firm earned ($0.52) earnings per share.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (9.82%), BlackRock Inc. (6.21%), Vanguard Group Inc. (4.61%), State Street Corp (1.82%), Dimensional Fund Advisors LP (1.50%) and Assenagon Asset Management S.A. (1.40%). Insiders that own company stock include David Apelian, Eldon C Mayer III, Evan Loh, Jeffrey S Glenn, Sriram Ryali and Thomas John Dietz.
View institutional ownership trends
.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $3.91.

How much money does Eiger BioPharmaceuticals make?

Eiger BioPharmaceuticals (NASDAQ:EIGR) has a market capitalization of $172.31 million and generates $12.14 million in revenue each year. The biotechnology company earns $-33,920,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The official website for the company is www.eigerbio.com. The biotechnology company can be reached via phone at (650) 272-6138, via email at ichoong@eigerbio.com, or via fax at 650-618-1621.

This page (NASDAQ:EIGR) was last updated on 12/7/2022 by MarketBeat.com Staff